Patents by Inventor John Rothman

John Rothman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating anxiety-related disorders
    Patent number: 11931329
    Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: March 19, 2024
    Assignee: YAMO PHARMACEUTICALS LLC
    Inventors: Steven Hoffman, John Rothman
  • Compositions And Methods For Treating Autism
    Publication number: 20230310358
    Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.
    Type: Application
    Filed: April 24, 2023
    Publication date: October 5, 2023
    Inventors: Steven Hoffman, John Rothman
  • METHODS OF USING BILE ACIDS TO TREAT VIRAL INFECTIONS
    Publication number: 20230172951
    Abstract: The disclosure is directed to methods of using hydrophilic bile acids for the treatment of viral infections.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 8, 2023
    Inventors: Steven HOFFMAN, John ROTHMAN
  • METHODS OF TREATING CONDITIONS CHARACTERIZED BY INSULIN DEFICIENCY IN ANIMALS
    Publication number: 20230165940
    Abstract: The present disclosure is directed to methods of treating conditions characterized by insulin deficiency in animals by trans dermal insulin administration.
    Type: Application
    Filed: April 8, 2021
    Publication date: June 1, 2023
    Inventors: Steven HOFFMAN, John ROTHMAN
  • Compositions and methods for treating autism
    Patent number: 11633372
    Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: April 25, 2023
    Assignee: YAMO PHARMACEUTICALS LLC
    Inventors: Steven Hoffman, John Rothman
  • Methods of treating SARS-CoV-2 infections
    Patent number: 11607418
    Abstract: The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: March 21, 2023
    Assignee: Tyme, Inc.
    Inventors: Steven Hoffman, John Rothman
  • COMPOSITIONS AND METHODS FOR TREATING ANXIETY-RELATED DISORDERS
    Publication number: 20230040681
    Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.
    Type: Application
    Filed: August 4, 2022
    Publication date: February 9, 2023
    Inventors: Steven Hoffman, John Rothman
  • Compositions and methods comprising KLK3 or FOLH1 antigen
    Patent number: 11446369
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: September 20, 2022
    Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yvonne Paterson, John Rothman, Vafa Shahabi
  • Compositions and methods for treating anxiety-related disorders
    Patent number: 11446268
    Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: September 20, 2022
    Assignee: YAMO PHARMACEUTICALS LLC
    Inventors: Steven Hoffman, John Rothman
  • CHEWABLE FORMULATIONS
    Publication number: 20220288000
    Abstract: The invention relates to tyrosine hydroxylase inhibitor compositions and methods of preparing and administering thereof. Specifically, the invention relates to an oral chewable formulation of a tyrosine hydroxylase inhibitor, particularly ?-methyl-DL-tyrosine.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 15, 2022
    Applicant: HOFFMAN TECHNOLOGIES LLC
    Inventors: Steven Hoffman, John Rothman
  • PERCUTANEOUS ANTI-MICROBIOTA FORMULATIONS
    Publication number: 20220241368
    Abstract: The present disclosure is directed to percutaneous compositions containing an antiseptic, an antibiotic, an antifungal agent, an antihelminth agent, an antiviral agent, or an NSAID.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 4, 2022
    Inventors: Steven Hoffman, John Rothman
  • SUSTAINED RELEASE FORMULATIONS
    Publication number: 20220211650
    Abstract: The invention relates to tyrosine hydroxylase inhibitor compositions and methods thereof. Specifically, the invention relates to a sustained release formulation of a tyrosine hydroxylase inhibitor, particularly ?-methyl-para-tyrosine.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 7, 2022
    Inventors: Steven HOFFMAN, John ROTHMAN
  • METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS
    Publication number: 20210379021
    Abstract: The present invention is directed to an improved method for preparing bisantrene, specifically bisantrene dihydrochloride, for intravenous administration, as well as to preparations of bisantrene dihydrochloride for intravenous administration. The present invention is also directed to methods for treatment of malignancies treatable by administration of bisantrene, which can include administration of additional anti-neoplastic agents, wherein the bisantrene is prepared by a method according to the present invention.
    Type: Application
    Filed: October 4, 2019
    Publication date: December 9, 2021
    Inventors: Daniel E. LEVY, John ROTHMAN
  • METHODS OF TREATING SARS-COV-2 INFECTIONS
    Publication number: 20210353645
    Abstract: The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.
    Type: Application
    Filed: January 6, 2021
    Publication date: November 18, 2021
    Inventors: Steven Hoffman, John Rothman
  • COMPOSITIONS AND METHODS FOR TREATING AUTISM
    Publication number: 20210338619
    Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering alpha-methyl-DL-tyrosine.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 4, 2021
    Inventors: Steven HOFFMAN, John ROTHMAN
  • Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
    Patent number: 11147800
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 19, 2021
    Assignee: Race Oncology Ltd.
    Inventors: William J. Garner, Arnie Franklin, John Rothman
  • Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
    Patent number: 11135201
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof. Such methods and compositions are particularly useful for treatment of malignancies.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 5, 2021
    Assignee: RACE ONCOLOGY LTD.
    Inventors: William J. Garner, Amie Franklin, John Rothman
  • TUMOR REDUCTION FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20210275467
    Abstract: The invention relates to tumor reducing compositions and methods thereof. Specifically, the invention relates to compositions comprising a combination of a sclerosing agent and a penetrating agent.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 9, 2021
    Applicant: TYME, INC
    Inventors: Steven Hoffman, John Rothman
  • PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20210169903
    Abstract: Methods of treating cancer or reducing tumor size by contacting a patient's cancer cells or tumor with an effective amount of a pharmaceutical composition as further defined herein.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 10, 2021
    Inventors: Steven Hoffman, John Rothman
  • Compositions And Methods For Treating Autism
    Publication number: 20210128508
    Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.
    Type: Application
    Filed: October 12, 2020
    Publication date: May 6, 2021
    Inventors: Steven Hoffman, John Rothman